Back to Agenda
Session 6: Novel Digital End Points
Session Chair(s)
Cécile Mathilde Ollivier, MS
Vice President, Global Affairs - Managing Director, Europe, Critical Path Institute, Netherlands
Solène Thieffry, MSC
Global RWE Policy Lead, UCB, Belgium
Most endpoints used in clinical trials are not necessarily patients-preferred nor easy to collect in routine care on the long term. Enhancing endpoints measurement continuously from clinical practice to real-word would facilitate better healthcare decision making for individual patients and population-level health. The aim of the session is to provide regulatory requirements and current use cases to develop novel digital endpoints that would help to bridge the gap in endpoints measurement across drug life cycle.
Speaker(s)
Regulatory Perspective on Digital Endpoints
Senior Director, EUCAN regulatory head GI, Takeda, Switzerland
Digital endpoints
Global Program Physician, Rare Disease Organization, UCB Biosciences, Germany
SARAhome - a new Clinical Tool for assessing Ataxia at home
, German Center for Neurodegenerative Diseases (DZNE), Germany
Have an account?